Ginkgo Bioworks’ Autonomous Laboratory Driven by OpenAI’s GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Research conducted in collaboration with OpenAI using Ginkgo’s cloud laboratory
Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis
GPT-5-driven autonomous lab executed over 36,000 experiments
Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science

BOSTON, Feb. 5, 2026 /PRNewswire/ — Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.

The study represents a real-world scientific application of Ginkgo’s autonomous lab. The collaborators combined OpenAI’s GPT-5 reasoning model with Ginkgo’s cloud laboratory infrastructure, built from its reconfigurable automation carts (RAC) technology and Catalyst automation software, to design, execute, and analyze experiments in an iterative, closed-loop workflow. GPT-5 was given internet access, a computer with data analysis packages, experimental (meta)data from prior iterations, and a preprint describing state of the art, and was able to operate like an experimental scientist – designing experiments, analyzing results, and refining its approach in response. In six rounds of experiments over the course of six months, it was able to design lower cost cell-free protein synthesis reaction compositions than had been shown in the scientific literature previously.

“By pairing a frontier large language model with an autonomous lab, we found reaction compositions that are notably cheaper than prior state of the art,” said Reshma Shetty, co-founder of Ginkgo Bioworks and co-author of the study. “We expect more and more experiments to be run on autonomous labs where reagent and consumables costs dominate the cost of an experiment. Lower cost reagents for protein production enable more data generation and thus more scientific progress per dollar spent.”

The autonomous lab achieved production of a standard benchmark protein, superfolder green fluorescent protein (sfGFP), at $422 per gram of protein in total reaction component costs, compared to a previously reported state of the art of $698 per gram, representing a 40% reduction under the experimental conditions described. Cell-free protein synthesis is widely used in biological research but has been limited by high material costs and complex optimization, making it an ideal stress test for autonomous experimentation.

“At OpenAI, this was the first time we were able to interface a frontier model with an autonomous lab to carry out experimentation at a very large scale,” said Joy Jiao, life sciences research lead at OpenAI and co-corresponding author of the study. “This success points to how AI systems can augment the experimental workflow, contributing to hypothesis generation, testing, and refinement based on real-world data.”

The autonomous lab executed more than 580 384-well plates, tested 36,000 reaction compositions, and generated nearly 150,000 experimental data points. Human involvement was primarily limited to reagent preparation, loading and unloading and system oversight, while experimental design, execution data interpretation, and hypothesis generation were handled by the GPT-5-driven autonomous lab. Notably, the model also proposed and prioritized new reagents to test, some of which independently anticipated findings from published research it had not been given access to.

To preclude the AI from proposing impractical, invalid, or hallucinatory experiments, every design was validated against a Pydantic model before execution, including checking plate layout, standards, controls, replication, reagent availability, and volume constraints. Only experiments that passed validation were eligible to run. Additional scoring prioritized scientific rigor and consideration of prior results. GPT-5 generated human-readable lab notebook entries documenting its analysis, observations, and rationale, providing transparency into its reasoning.

“This is AI doing real experimental science: designing experiments, running them, and learning from the results,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “AI combined with autonomous labs is needed to keep the United States competitive in science worldwide – the recently announced Genesis Mission led by the U.S. Department of Energy to bring AI into science is leading the way here and I’m excited that our results with OpenAI show this approach is working.”

The Pydantic model is being released open source and the AI-improved cell-free reaction mix can be ordered by the scientific community at https://reagents.ginkgo.bio/

About the Preprint
The findings are described in a scientific preprint that has not yet undergone peer review. The full manuscript, “Using a GPT-5-driven autonomous lab to optimize the cost and titer of cell-free protein synthesis,” is available on OpenAI’s website and will soon be available on bioRxiv.

About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo’s in-house autonomous lab is also available as a “cloud lab” through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo’s autonomous laboratories. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Contacts

Ginkgo Bioworks investor contact:
[email protected]

Ginkgo Bioworks media contact:
[email protected]

SOURCE Ginkgo Bioworks

Source link